Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9Y6C5

UPID:
PTC2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9Y6C5; O95341; O95856; Q53Z57; Q5QP87; Q6UX14

BACKGROUND:
The Protein patched homolog 2, with its role in the regulation of cellular proliferation and possible involvement in skin development, acts as a key component in the Sonic hedgehog (SHH) signaling pathway. This protein's function underscores its importance in fundamental biological processes and disease mechanisms.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Protein patched homolog 2 could open doors to potential therapeutic strategies for combating diseases such as Medulloblastoma and Basal cell carcinoma, where it plays a significant role. Targeting this protein could offer new avenues for treatment in these malignancies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.